ARCHIVES

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief; NCAB Goes Along With NCI Staff In Funding EORTC Statistical Center Grant Out Of Priority Sequence

November 20, 1981

DCT Board Okays Concepts For New Radiation Studies

June 12, 1987

Cooperative Group Competing Renewals May Be Funded Only at 70-80% Of Amounts Recommended By CCIRC

January 2, 1981

Program Announcements For Tobacco Research

January 21, 1983

Caris Life Sciences Lays Off Estimated 20 Percent of Staff

October 24, 2014

Clinical Research Needs Payment Mechanism, Kerrey

February 4, 1994